Q3 2026 West Pharmaceutical Services Earnings Conference Call - WEST PHARMACEUTICAL SERVICES INC

Explicit Guidance:

• Full-Year 2026 Revenue: Revised upward to $3.41–3.42 billion (prior: $3.345–3.38 billion); implies 11.3%–11.6% organic sales growth (prior: 10–11%).
• Full-Year 2026 EPS: Revised upward to $9.38–9.48 (prior: $8.85–9.05); represents 29–30% year-over-year growth.
• Q4 2026 Revenue: Implied guidance of $820–830 million, targeting 6–7% organic growth.
• Capital Expenditures (CapEx): Full-year 2026 expected between $215–220 million (approx. 6–8% of revenue); future spending anticipated to remain within the 6–8% revenue corridor.
• Operating Margins: Full-year 2026 adjusted operating margins expected to expand by ~300 basis points year-over-year, driven by gross margin expansion and SG&A leverage, exceeding the long-term 100 bps/annual improvement construct.
• Financial Assumptions:
  • Foreign Exchange (FX): Full-year benefit of 120 basis points (offset by ~160 bps negative impact from SmartDose 3.5 divestiture on reported growth).
  • Net Interest Income: Projected $5 million for full year.
  • Tax Rate: Full-year adjusted tax rate expected slightly below 18%.
  • Affiliate Profits: Expected $18 million.
  • Diluted Shares Outstanding: Projected 71.4 million for the full year.
  • Dividends: 34th consecutive year of dividend increases, with an 18% increase announced in the quarter.
  • Share Repurchases: Continue repurchase plans; $685 million repurchased YTD in 2026.
• 2027 Guidance: Management intends to introduce full-year 2027 guidance during the Q4 2026 earnings call in February 2027.

Business-Segment Outlook:

• Proprietary Products (HVP Components):
  • Represents 53% of total revenues; revenue growth expected to exceed company-wide rates.
  • GLP-1 Segment: Strong acceleration (growth "well into the 30s" organically in Q3); expected to maintain long-term growth via adoption of next-generation molecules, new therapeutic categories, and generic expansion.
  • Non-GLP-1 HPP: Growing "high teens" organically; driven by biologics growth and HPP upgrades.
  • HVP Devices (Crystal Zenith/Admin Systems): Expecting "broad-based" growth; Q4 expected to be slightly "lumpy" compared to Q3 strong finish, but portfolio (including next-gen SmartDose 10) remains positive.
  • Mix Shift: HVP mix expected to rise over time as it grows faster than the overall company; biologics component expected to benefit from record clinical development pipelines.
• West Vantage:
  • Strategy shifting to higher value-added drug handling; legacy programs (e.g., CGM) rolling off, offset by ramp-up of new programs.
  • Expected to have a muted effect on segment growth for the current year and next year.
  • Funnel of high-value contract opportunities remains strong; Q4 performance expected to align with expectations.
• SmartDose 3.5: Divestiture closed; $55 million revenue expected in H2 2026, with Q4 2026 revenue of $25 million. Future organic growth calculations will exclude this, creating a ~290 basis point headwind to reported growth in 2027.
• Asia-Pacific: 42% organic growth in Q3 (led by India and China); GLP-1 introduction and innovative drug development driving early-stage expansion; significant future opportunity anticipated.

Market and Competitive Outlook:

• Injectable Market: Viewed as having long-term runway for volume growth and HPP upgrades across existing and new drugs.
• Regulatory Tailwinds: Annex 1 in Europe driving HPP upgrades; expected global adoption of similar contamination standards (e.g., US HHS draft guidance). This is a multi-year tailwind with over 200 upgrade projects added in 2026.
• Customer Relationships: Strategy to deepen strategic partnerships for better demand planning, capacity alignment, and faster innovation adoption; customers increasingly seeking supply chain simplification and consolidation.
• Pricing: Long-term planning assumption remains 2–3% organic price growth; Q3 pricing contribution was ~4% due to specific environment but expected to normalize.
• Competitive Position: Firmly on the "very short list" of preferred partners; enviable leadership position expected to be strengthened by continuous improvement and strategic customer alignment.

Macro / Industry Outlook:

• Biologics Pipeline: Record number of compounds in clinical development with increasing percentage of biologics; viewed as a primary driver for injection delivery demand.
• GLP-1 Landscape: Bullish on the class; growth expected to persist despite concerns regarding generics, multidose, and orals due to access expansion (e.g., Medicare Bridge Program) and new molecule development.
• Geopolitical/Regulatory: Regulatory frameworks globally are raising the bar on containment systems, expected to drive global HPP upgrades beyond Europe.
• Currency: FX volatility is expected to impact reported growth (e.g., dollar strengthening in Q3), but management remains confident in organic performance.

Strategic Initiatives:

• Capacity Expansion: Launching a new wave of capital investments to expand HVP finishing capacity in Europe and the US.
• Timeline: Lead time for new capacity projects estimated at 18–24 months for meaningful contribution to growth.
• Efficiency & Continuous Improvement: Focusing on de-bottlenecking current facilities via automation and digitization (e.g., Eschweiler site example); aiming to increase output without necessarily acquiring new units.
• M&A Strategy: Organic growth remains the primary focus; M&A bar is set "incredibly high" to ensure transactions amplify the financial profile and align with customer needs for supply chain consolidation.
• West Vantage Optimization: Continuing to execute strategy of replacing legacy contracts with higher value-added work to strengthen the segment's long-term contribution.

Risks and Headwinds to Outlook:

• SmartDose 3.5 Divestiture: Creating a 160 basis point negative impact on 2026 reported growth and a 290 basis point headwind to 2027 reported growth.
• West Vantage Mix: Muted growth expected in 2026/2027 due to the lag between legacy roll-offs and new program ramps.
• FX Volatility: Strengthening dollar could negatively impact reported revenue (already priced into prudent guidance); Q4 guidance absorbed potential negative FX shifts.
• Capacity Constraints: Current growth relies on shifting from existing footprint; execution risk on ramping new finishing capacity (18–24 month lead time).
• Regulatory Pace: While a tailwind, the timing of global regulatory adoption (e.g., US HHS guidance vs. EU Annex 1) could vary, though management views it as a consistent global trend.

Management Tone on the Future:

• Confidence: "Very pleased," "super excited," "bullish," and "confident" regarding 2026 full-year finish and long-term prospects.
• Strategic Clarity: New CEO emphasizes "continuous improvement" and "strategic customer relations" as primary levers for unlocking value.
• Discipline: Commitment to maintaining CapEx within the 6–8% range and high discipline on M&A; prioritizing "organic profile" strength.
• Optimism: Margins viewed as having "incremental strength" and "underappreciated opportunities" for further expansion beyond the current 300 bps beat.
• Hedging: Guidance is described as "prudent" to absorb FX headwinds and West Vantage pull-forward effects.

Miscellaneous:

• Free Cash Flow: $278 million for first 9 months 2026 (down 5% YoY due to AR and inventory increases); expected to improve in Q4.
• Divestiture Impact: SmartDose 3.5 revenues ($55M H2 2025, $12M Q3 2026) excluded from organic growth calculations.
• Global Operations: Adding and training new shifts to optimize global network; success attributed to strong teamwork and mission-driven culture.